[Involvement of PML proteins in treatment of acute promyelocytic leukemia with arsenic trioxide].
Zhejiang Da Xue Xue Bao Yi Xue Ban
; 47(5): 541-551, 2018 05 25.
Article
em Zh
| MEDLINE
| ID: mdl-30693698
ABSTRACT
Promyelocytic leukemia (PML) protein, a tumor suppressor, plays an important role in patients with acute promyelocytic leukemia (APL) receiving arsenic trioxide (As2O3) therapy. APL is a M3 subtype of acute myeloid leukemia (AML), which is characterized by expression of PML-RARα (P/R) fusion protein, leading to the oncogenesis. As2O3 is currently used as the first-line drug for patients with APL, and the mechanism may beAs2O3 directly binds to PML part of P/R protein and induces multimerization of related proteins, which further recruits different functional proteins to reform PML nuclear bodies (PML-NBs), and finally it degraded by SUMOylation and ubiquitination proteasomal pathway. Gene mutations may lead to relapse and drug resistance after As2O3 treatment. In this review, we discuss the structure and function of PML proteins; the pathogenesis of APL induced by P/R fusion protein; the involvement of PML protein in treatment of APL patient with As2O3; and explain how PML protein mutations could cause resistance to As2O3 therapy.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leucemia Promielocítica Aguda
/
Proteína da Leucemia Promielocítica
/
Trióxido de Arsênio
Limite:
Humans
Idioma:
Zh
Ano de publicação:
2018
Tipo de documento:
Article